Organon & Co. Common Stock vs Wynn Resorts, Limited — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Wynn Resorts, Limited trades at $74 (market cap $7.79B). The key difference: Wynn Resorts, Limited is far larger — about 2.2× Organon & Co. Common Stock's market cap, and Wynn Resorts, Limited pays the higher dividend (1.32%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Wynn Resorts, Limited for 77 Days on average.
| OGN | WYNN | |
|---|---|---|
Market Cap | $3.62B | $7.79B |
Volume | 2,892,999 | 1,551,566 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $133.09 |
52-Week Low | $5.70 | $73.73 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $11.04B | $18.04B |
Dividend Yield | 0.58% | 1.32% |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Wynn Resorts (WYNN) trades at $73.73, down 1.64% on the day, amid a bearish technical signal. The stock shows strong analyst support with a 64% buy rating and a consensus price target of $130.73, implying significant upside. Recent Q2 2026 earnings beat expectations, driven by Macau strength, though U.S. margins face pressure. The company maintains solid revenue growth, with 2026 revenue projected at $7.4B, but net cash flow remains negative due to high capital expenditures for expansion projects like Wynn Al Marjan.
The outlook for WYNN is cautiously optimistic, with Macau recovery and new project potential offering growth opportunities. However, risks include elevated debt levels, rising capex, and competitive pressures. Investors should weigh the substantial upside projected by analysts against execution risks and macroeconomic sensitivities affecting the gaming sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →